Copper‐Single‐Atom Coordinated Nanotherapeutics for Enhanced Sonothermal‐Parallel Catalytic Synergistic Cancer Therapy (Adv. Healthcare Mater. 23/2023)

miRNA nanotherapeutics for cancer.

MicroRNAs (miRNAs) are noncoding RNA molecules that regulate gene expression through diverse mechanisms. Increasing evidence suggests that miRNA-based therapies, either restoring or repressing miRNA expression and activity, hold great promise. However, the efficient delivery of miRNAs to target tissues is a major challenge in the transition of miRNA therapy to the clinic. Cationic polymers or v...

Coordinated Enhanced Surveillance with Healthcare Entities for Mass Gathering Events

Introduction Mass gatherings can result in morbidity and mortality from communicable and non-communicable diseases, injury, and bioterrorism. Therefore, it is important to identify event-related visits as opposed to community-related visits when conducting public health surveillance1. Previous mass gatherings in Virginia have demonstrated the importance of implementing enhanced surveillance to ...

Metamaterials: Snapping Mechanical Metamaterials under Tension (Adv. Mater. 39/2015).

By exploiting snap-through instabilities, D. Pasini and co-workers design a damage-tolerant mechanical metamaterial that snaps sequentially under tension, thereby accommodating a very large deformation up to 150%. On page 5931, they describe how the nonlinear mechanical response of the metamaterial can be robustly programmed by tuning the architecture of its unit cell.

Targeted nanotherapeutics in cancer

Beta-lapachone micellar nanotherapeutics for non-small cell lung cancer therapy.

Lung cancer is the leading cause of cancer-related deaths with current chemotherapies lacking adequate specificity and efficacy. Beta-lapachone (beta-lap) is a novel anticancer drug that is bioactivated by NAD(P)H:quinone oxidoreductase 1, an enzyme found specifically overexpressed in non-small cell lung cancer (NSCLC). Herein, we report a nanotherapeutic strategy that targets NSCLC tumors in t...